Medpace (NASDAQ:MEDP) Stock Acquired Rep. David Taylor

Representative David Taylor (R-Ohio) recently bought shares of Medpace Holdings, Inc. (NASDAQ:MEDP). In a filing disclosed on February 02nd, the Representative disclosed that they had bought between $1,001 and $15,000 in Medpace stock on January 29th. The trade occurred in the Representative’s “DAVID TAYLOR TRUST > SARDINIA READY MIX 401(K) – DAVE” account.

Representative David Taylor also recently made the following trade(s):

• Purchased $1,001 – $15,000 in shares of Microsoft (NASDAQ:MSFT) on 1/29/2026.
• Purchased $1,001 – $15,000 in shares of Broadcom (NASDAQ:AVGO) on 1/29/2026.
• Sold $1,001 – $15,000 in shares of Amgen (NASDAQ:AMGN) on 1/29/2026.
• Sold $1,001 – $15,000 in shares of Vertex Pharmaceuticals (NASDAQ:VRTX) on 1/29/2026.
• Purchased $1,001 – $15,000 in shares of Salesforce (NYSE:CRM) on 1/29/2026.
• Purchased $1,001 – $15,000 in shares of Amazon.com (NASDAQ:AMZN) on 1/29/2026.
• Sold $1,001 – $15,000 in shares of Procter & Gamble (NYSE:PG) on 1/29/2026.
• Purchased $1,001 – $15,000 in shares of Installed Building Products (NYSE:IBP) on 1/29/2026.
• Purchased $1,001 – $15,000 in shares of Prologis (NYSE:PLD) on 1/29/2026.
• Purchased $1,001 – $15,000 in shares of JPMorgan Chase & Co. (NYSE:JPM) on 1/29/2026.

Medpace Trading Down 1.2%

MEDP stock opened at $561.52 on Thursday. The firm’s 50-day moving average is $581.91 and its two-hundred day moving average is $536.26. The company has a market capitalization of $15.82 billion, a price-to-earnings ratio of 39.27, a price-to-earnings-growth ratio of 1.91 and a beta of 1.42. Medpace Holdings, Inc. has a 52 week low of $250.05 and a 52 week high of $628.92.

Institutional Trading of Medpace

Hedge funds have recently modified their holdings of the business. NewEdge Advisors LLC lifted its stake in Medpace by 22.1% in the 1st quarter. NewEdge Advisors LLC now owns 1,048 shares of the company’s stock worth $319,000 after acquiring an additional 190 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its holdings in shares of Medpace by 3.8% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 81,817 shares of the company’s stock valued at $24,929,000 after purchasing an additional 3,010 shares during the period. Geneos Wealth Management Inc. lifted its position in shares of Medpace by 64.9% in the first quarter. Geneos Wealth Management Inc. now owns 94 shares of the company’s stock worth $29,000 after purchasing an additional 37 shares in the last quarter. Sivia Capital Partners LLC purchased a new stake in shares of Medpace in the second quarter worth approximately $296,000. Finally, Truist Financial Corp boosted its holdings in shares of Medpace by 10.2% during the second quarter. Truist Financial Corp now owns 12,898 shares of the company’s stock worth $4,048,000 after purchasing an additional 1,197 shares during the period. Hedge funds and other institutional investors own 77.98% of the company’s stock.

Wall Street Analysts Forecast Growth

Several brokerages recently weighed in on MEDP. Truist Financial set a $555.00 target price on Medpace in a research note on Monday, October 27th. Zacks Research downgraded shares of Medpace from a “strong-buy” rating to a “hold” rating in a report on Monday, January 12th. Mizuho set a $660.00 target price on shares of Medpace in a report on Friday, January 9th. BMO Capital Markets assumed coverage on shares of Medpace in a research report on Thursday, November 13th. They issued a “market perform” rating and a $600.00 price target on the stock. Finally, TD Cowen reaffirmed a “sell” rating on shares of Medpace in a report on Friday, October 24th. Two equities research analysts have rated the stock with a Buy rating, ten have issued a Hold rating and three have assigned a Sell rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Reduce” and a consensus price target of $491.27.

Insider Activity at Medpace

In other Medpace news, CEO August J. Troendle sold 59,025 shares of the business’s stock in a transaction dated Monday, November 24th. The stock was sold at an average price of $607.78, for a total value of $35,874,214.50. Following the transaction, the chief executive officer owned 774,602 shares in the company, valued at $470,787,603.56. The trade was a 7.08% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, VP Susan E. Burwig sold 20,000 shares of the firm’s stock in a transaction dated Monday, November 24th. The stock was sold at an average price of $609.15, for a total value of $12,183,000.00. Following the sale, the vice president directly owned 27,500 shares of the company’s stock, valued at $16,751,625. This trade represents a 42.11% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last quarter, insiders sold 320,192 shares of company stock worth $192,909,762. Company insiders own 20.30% of the company’s stock.

About Representative Taylor

David Taylor (Republican Party) is a member of the U.S. House, representing Ohio’s 2nd Congressional District. He assumed office on January 3, 2025. His current term ends on January 3, 2027.

Taylor (Republican Party) ran for election to the U.S. House to represent Ohio’s 2nd Congressional District. He won in the general election on November 5, 2024.

David Taylor graduated from Amelia High School. Taylor earned degrees from Miami University (Ohio) and the University of Dayton School of Law. Taylor’s career experience includes working as an attorney and as a businessman at Sardinia Ready Mix, Inc.

Medpace Company Profile

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.